A German study has found that FDG PET can differentiate between responders and nonresponders two weeks after the initiation of neoadjuvant chemotherapy for advanced adenocarcinoma of the esophagogastric junction.
A German study has found that FDG PET can differentiate between responders and nonresponders two weeks after the initiation of neoadjuvant chemotherapy for advanced adenocarcinoma of the esophagogastric junction.
"This is the first study to apply PET results from early metabolic response assessment to clinical decision-making in the treatment of common solid tumors," said Dr. Ken Herrmann, a resident in the nuclear medicine department at the Technical University in Munich. The study was initiated by Dr. Florian Lordick in the university's surgery department. Results were presented in June at the 2007 Society of Nuclear Medicine meeting.
F-18 FDG PET was performed on 110 patients with potentially R0 resectable adenocarcinoma of the esophagogastric junction to assess for metabolic response.
Patients with a greater than 35% decrease in tumor standardized uptake value (SUV) after two weeks of neoadjuvant platin/5-fluorouracil-based chemotherapy compared with baseline were defined as metabolic responders. They continued on chemotherapy for 12 weeks before surgery.
Patients with less than a 35% SUV decrease were classified as metabolic nonresponders. Chemotherapy was stopped after the initial two weeks for nonresponders, and they proceeded to immediate surgery. Follow-up CT scans and endoscopy were performed every three months in the first year and every six months thereafter.
The overall response rate after two weeks of the chemotherapy was 49%. A total of 104 patients underwent resection (subtotal esophagectomy 70%, extended gastrectomy 30%).
Major histologic remissions (less than 10% residual tumor) were observed in 58% of metabolic responders versus none for the metabolic nonresponders (P
After a median follow-up of 2.3 years, metabolic responders have obtained a significantly better median event-free survival of 29.7 months versus 14.1 months for metabolic nonresponders (P
"The outcome for metabolic responders turned out to be remarkably favorable, compared with metabolic nonresponders," Herrmann said.
For more information from the Diagnostic Imaging archives:
PET/CT predicts chemo response in lung cancer patients
Imaging assume broader role in assessing therapy
PET could become go-to modality for gauging response to therapy
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.